This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BioScrip Appoints Tricia Huong Thi Nguyen To Board Of Directors

ELMSFORD, N.Y., Jan. 14, 2014 /PRNewswire/ -- BioScrip®, Inc. (NASDAQ: BIOS) today announced that it has appointed Tricia Huong Thi Nguyen, M.D., 41, to its Board of Directors, effective immediately. The addition of Dr. Nguyen increases the size of the Board from eight to nine members, eight of whom are independent and all of whom are elected annually. As an independent director, Dr. Nguyen will serve on the Nominating and Governance Committee and the Corporate Strategy Committee and will stand for election at the Company's 2014 Annual Meeting of Stockholders.

Dr. Nguyen is an industry veteran with more than 20 years of leadership experience in managed care and health insurance. She currently serves as the president of Texas Health Population Health, Education, Research and Innovation Center, an organization devoted to sharing best practices, disseminating information about innovative approaches, leading physician-directed population health initiatives and coordinating community-based well-being collaboration.

"Dr. Nguyen has a passion for patient care and a deep understanding of our industry, and we are pleased to welcome her to the BioScrip Board of Directors," said Myron Holubiak, Chairman of the Board. "Dr. Nguyen's extensive healthcare expertise, combined with her appreciation of payer relationships, will help BioScrip continue to advance its strategy toward a home infusion and post-acute care model. On behalf of the entire Board, we look forward to benefiting from her insights and contributions."

Until September 2013, Dr. Nguyen served as the Chief Medical Officer of Banner Health Network, where she oversaw the activities of more than 2,500 physicians. Between 2008 and 2011 she held senior positions at Blue Cross Blue Shield in Kansas City and Florida. From August 2005 to April 2008, Dr. Nguyen was Vice President and Market Medical Officer of Humana, Inc., a managed health care company that markets and administers health insurance. Dr. Nguyen received her medical degree from the University of Missouri's Columbia School of Medicine and her Bachelors of Science from Creighton University School of Pharmacy. She also holds a Medical Management Executive MBA from the University of Texas at Dallas.

About BioScrip, Inc.

BioScrip, Inc. is a leading national provider of infusion and home care solutions. BioScrip partners with physicians, healthcare payors, government agencies, hospital systems and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by quality, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion and home care services from 108 locations across 29 states.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs